These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 16689025)

  • 1. A method classifying biologics for formulary decision making.
    Broder MS; Reissman D
    Manag Care Interface; 2006 Apr; 19(4):30-2. PubMed ID: 16689025
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Formulary decision-making considerations: COX-2 inhibitors.
    Shaya FT; Wong W; Shin JY; Martin L; Samant N
    Manag Care Interface; 2004 Nov; 17(11):29-36, 41. PubMed ID: 15573802
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical monograph for drug formulary review: systemic agents for psoriasis/psoriatic arthritis.
    Fisher VS
    J Manag Care Pharm; 2005; 11(1):33-55. PubMed ID: 15667232
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Managing the expanded use of biologics across therapeutic areas: an example from b-cell targeted therapies.
    Cohen M; Morrow T; Penna P
    Am J Manag Care; 2006 Mar; 12(2 Suppl):S24-37; quiz S38. PubMed ID: 16551202
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of health-related quality of life information in managed care formulary decision-making.
    Wu WK; Sause RB; Zacker C
    Res Social Adm Pharm; 2005 Dec; 1(4):579-98. PubMed ID: 17138497
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Understanding, creating, and working with formulary systems.
    Quinn CE; Barisano A
    Am J Manag Care; 1999 Oct; 5(10):1311-7; quiz 1318-9. PubMed ID: 10622996
    [No Abstract]   [Full Text] [Related]  

  • 7. The drug formulary decision-making process.
    Brehany J; Cohen P; Sax MJ
    Healthplan; 1999; 40(3):85-92. PubMed ID: 10538088
    [No Abstract]   [Full Text] [Related]  

  • 8. From conventional to cutting edge: the new era of biologics in treatment of psoriasis.
    Tzu J; Kerdel F
    Dermatol Ther; 2008; 21(2):131-41. PubMed ID: 18394087
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The case for a value-based formulary: striving for total lowest net cost.
    Weart W; Bauman GR
    Manag Care Interface; 2007 Apr; 20(4):42-7. PubMed ID: 17474330
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence-based decision making in managed care pharmacy.
    Penna P
    Manag Care Interface; 2002 May; 15(5):43-4. PubMed ID: 12024870
    [No Abstract]   [Full Text] [Related]  

  • 11. Formulary decision making and acute exacerbations of chronic bronchitis.
    Penna P
    Manag Care Interface; 2001 Feb; 14(2):50-1. PubMed ID: 11228816
    [No Abstract]   [Full Text] [Related]  

  • 12. Weighing the evidence: trends in managed care formulary decision making.
    de Lissovoy G
    J Clin Psychiatry; 2003; 64 Suppl 17():29-32. PubMed ID: 14680425
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Academy of Managed Care Pharmacy's format for formulary submission.
    Penna P
    Manag Care Interface; 2001 Jun; 14(6):61-2. PubMed ID: 11432152
    [No Abstract]   [Full Text] [Related]  

  • 14. Raising the bar in the formulary decision process.
    Navarro RP
    Manag Care Interface; 1999 Jul; 12(7):51, 54. PubMed ID: 10539501
    [No Abstract]   [Full Text] [Related]  

  • 15. Formulary submission process catches on ... slowly.
    Cross M
    Manag Care; 2002 Nov; 11(11):32-6. PubMed ID: 12491856
    [No Abstract]   [Full Text] [Related]  

  • 16. Long-term efficacy of biologics in the treatment of psoriasis: what do we really know?
    Alwawi EA; Krulig E; Gordon KB
    Dermatol Ther; 2009; 22(5):431-40. PubMed ID: 19845720
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Medication adherence and health care costs associated with biologics in Medicaid-enrolled patients with psoriasis.
    Bhosle MJ; Feldman SR; Camacho FT; Timothy Whitmire J; Nahata MC; Balkrishnan R
    J Dermatolog Treat; 2006; 17(5):294-301. PubMed ID: 17092860
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Do P&T committees have enough power? Plans and PBMs are divided about sharing drug prices with clinicians. Is it better to have an administrative committee determine the formulary?
    Cross M
    Manag Care; 2007 Apr; 16(4):39-42. PubMed ID: 17491288
    [No Abstract]   [Full Text] [Related]  

  • 19. Any willing provider meets the formulary.
    Barrueta A
    Health Syst Rev; 1995; 28(4):20, 22-3. PubMed ID: 10144359
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Showing outcomes and proving value brings success.
    Fullerton DS; Atherly D; Sullivan SD
    Manag Care Interface; 2001 Jun; 14(6):63-5, 71. PubMed ID: 11432153
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.